# Why GLP-1 Drugs Make You Tired, and What Nobody Has Studied

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-31

Canonical page: https://glpwatchdog.org/research/glp1-fatigue-what-causes-it

> Fatigue runs 11% against 5% on placebo, and rises with dose: 5% to 9% to 11%. That dose-response hints that the drug itself contributes, although higher doses also take off more weight, and almost nothing else has been studied.

## Key points

- Label, main weight-management trials: fatigue 11% on semaglutide 2.4 mg against 5% on placebo.
- Dose-dependent in the 7.2 mg trial: 5% placebo, 9% at 2.4 mg, 11% at 7.2 mg.
- There is essentially no drug-specific research on it; the explanations are inference.
- Worth checking rather than assuming: thyroid, iron, B12, sleep apnea, mood.

Fatigue is in the label, it is roughly twice as common as on placebo, and it gets more common as the dose goes up: **5%** on placebo, **9%** at 2.4 mg, **11%** at 7.2 mg.[1] That dose-response is the most useful thing anyone can tell you about it, because it is the strongest available hint that the drug itself contributes, although higher doses also take off more weight. Beyond that, almost nobody has studied it, and what follows is reasoning rather than evidence.

## What the label counted

In the main adult weight-management trials, covering 2,116 people on semaglutide 2.4 mg, fatigue was reported by 11% against 5% on placebo.[1] It sits in the adverse reactions table alongside nausea and [headache](https://glpwatchdog.org/research/glp1-headache-and-intracranial-pressure), in the common, generally self-limiting group, and not in any warning section.

A separate table covering the 7.2 mg dose reports the three-way comparison: 5% on placebo, 9% at 2.4 mg, 11% at 7.2 mg.[1]

> More drug, more tiredness. That pattern points toward the drug itself, and it is the closest thing on the label to the [brain fog](https://glpwatchdog.org/research/glp1-brain-fog) people describe.

A dose-response relationship is one of the classic arguments for causation. If fatigue were simply a consequence of eating less or losing weight, you would expect it to track weight loss rather than milligrams. Higher doses do produce more weight loss, but the stepwise pattern across three arms is at least suggestive that the drug contributes directly.

## What is probably going on

This section is inference. There is no trial that took people with fatigue on a GLP-1, tested an explanation, and reported a result. Instead, several well-established mechanisms plausibly apply, each with its own evidence base elsewhere.

1. **You are eating substantially less.** A large calorie deficit produces tiredness in anyone, by any method. This is the most likely single contributor and the least specific to these drugs.
2. **Dehydration.** Nausea, vomiting and diarrhea all reduce fluid intake and increase losses, and dehydration causes fatigue well before it causes anything worse. It is also the mechanism behind the acute kidney injury the label warns about (see [kidneys](https://glpwatchdog.org/research/glp1-and-your-kidneys)).
3. **Under-eating protein specifically.** Appetite suppression tends to cut protein first, because protein-rich foods are the ones that feel heaviest. Our [protein calculator](https://glpwatchdog.org/tools/glp1-protein-calculator) works a target.
4. **Losing lean tissue.** Roughly a quarter to a third of weight lost is lean mass, which is comparable to what lifestyle programs cost ([the lean mass article](https://glpwatchdog.org/research/glp1-hair-loss-and-muscle-loss) covers it). Less muscle means the same task takes more of what you have. Whether it also causes aches has never been tested; [what the trials counted for joint and back pain](https://glpwatchdog.org/research/glp1-joint-pain-back-pain-and-aches) sets out what is known.
5. **Low blood sugar, if you take something else for it.** Fatigue is a hypoglycemia symptom, and the risk lives with insulin and sulfonylureas rather than the GLP-1. [The low blood sugar article](https://glpwatchdog.org/research/glp1-low-blood-sugar-risk) sets that out.

> **Notice what that list is.** Every item is well evidenced *as a cause of fatigue in general*, and none has been demonstrated as the cause of fatigue *on these drugs specifically*. That is a real distinction and most articles on this topic blur it. The list is a reasonable place to start looking, not a set of findings.

## What is worth checking rather than assuming

Fatigue is the least specific symptom in medicine, and starting a new drug is exactly when a different cause gets attributed to it. The things worth ruling out are cheap to check and common in this population.

- **Thyroid function**, which is a routine test and a routine cause.
- **Iron and B12**. Eating much less for months carries a risk of falling short on micronutrients,[2] and a shortfall in either one causes exactly this.
- **Sleep apnea**, which is common in this population and improves with weight loss (see [sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea)).
- **Mood**, because low energy and low mood are hard to tell apart from the inside.

None of that is a reason to assume the drug is innocent. It is a reason not to assume it is guilty, which is what happens when a new medicine gets blamed for everything that follows it. The same logic applies to a drop in [sex drive on a GLP-1](https://glpwatchdog.org/research/glp1-and-sex-drive).

## When it is not ordinary tiredness

> Fatigue that arrives with a racing heart, dizziness on standing, or an inability to keep fluids down is a dehydration picture rather than a tiredness one, and it is the pattern that precedes kidney injury. Fatigue with confusion, [sweating](https://glpwatchdog.org/research/glp1-feeling-cold-and-night-sweats) or shakiness in someone taking insulin or a sulfonylurea should be treated as low blood sugar until proven otherwise. Both are same-day problems.

## Frequently asked questions

### Is fatigue a side effect of GLP-1 drugs?

Yes, and it is in the label. In the adult weight-management trials it was reported by 11% of people on semaglutide 2.4 mg against 5% on placebo, and it sits among the common, generally self-limiting effects rather than in a warning section.

### Does it get worse at higher doses?

The label's figures suggest so: 5% on placebo, 9% at 2.4 mg and 11% at 7.2 mg. A stepwise increase across three arms is one of the classic arguments that a drug is causing something rather than merely being present.

### What causes it?

Nobody has established that. There is essentially no drug-specific research on fatigue with these medicines, so the usual explanations (a large calorie deficit, dehydration from the gastrointestinal effects, low protein intake, lean tissue loss, and low blood sugar in people also taking insulin) are reasoning from established mechanisms rather than findings about this drug.

### Will it go away?

Often it eases as the dose settles, in the same pattern as the other early effects, though nobody has measured that specifically for fatigue. If it worsens after each dose increase, that fits the dose-response the label shows and is worth raising.

### What should I get checked?

Thyroid function, iron and B12 are cheap, routine checks for common causes, and iron and B12 can both run low when intake stays down. Sleep apnea and mood are both worth considering. Starting a new drug is exactly when a different cause gets wrongly attributed to it.

## References

1. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions: fatigue 11% vs 5% placebo (2.4 mg, N=2,116) and 5%/9%/11% across placebo, 2.4 mg and 7.2 mg (N=1,311) (revised 06/2026). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Kwaśny A, Słoma-Krześlak M, Kostelecki G, et al. Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics. Adv Clin Exp Med. 2026. PMID: 42823936. DOI: 10.17219/acem/235937. https://pubmed.ncbi.nlm.nih.gov/42823936/

---

Cite as: GLP Watchdog, Nora Bissett, "Why GLP-1 Drugs Make You Tired, and What Nobody Has Studied", published 2026-08-19, updated 2026-10-31. https://glpwatchdog.org/research/glp1-fatigue-what-causes-it

Canonical HTML page: https://glpwatchdog.org/research/glp1-fatigue-what-causes-it

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
